Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacia & Upjohn: Bioinformatics Will Be Major R&D Focus in 1998


LONDON--In releasing its third-quarter results late last month, Pharmacia & Upjohn here said it plans to focus future R&D investments on "obtaining leading-edge research technologies, especially in genomics and bioinformatics, to aid in drug discovery and development." For the quarter the company's R&D expenditures fell 18.8 percent, from $330 million to $268 million; for the nine months year-to-date, they fell 10.8 percent, from $933 million to $832 million. By comparison, the company's net earnings fell 61.2 percent, from $204 million to $79 million, for the quarter, but rose 34.3 percent, from $336 million to $451 million, for the nine-month interval.

As a percentage of sales, R&D at Pharmacia & Upjohn accounted for 17.3 percent in the third quarter of 1997, compared to 19.2 percent a year ago, and 17 percent for the past nine months this year, compared to 17.8 percent in 1996. The company said it is in the midst of a comprehensive, worldwide restructuring and turnaround program.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.